Next Article in Journal
Acquisition of Genetic Aberrations by Activation-Induced Cytidine Deaminase (AID) during Inflammation-Associated Carcinogenesis
Next Article in Special Issue
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)
Previous Article in Journal
Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
Previous Article in Special Issue
Enhancing Photodynamyc Therapy Efficacy by Combination Therapy: Dated, Current and Oncoming Strategies
Open AccessReview

TRAF4, at the Crossroad between Morphogenesis and Cancer

Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UMR 7104 CNRS, U964 INSERM, Université de Strasbourg, BP 10142, 67404 Illkirch, C.U. de Strasbourg, France
Author to whom correspondence should be addressed.
Cancers 2011, 3(2), 2734-2749;
Received: 12 May 2011 / Revised: 16 June 2011 / Accepted: 17 June 2011 / Published: 21 June 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)


Tumor Necrosis Factor Receptor-Associated Factor 4 (TRAF4) is a gene whose expression is altered in cancers. It is overexpressed in a variety of carcinomas of different origins, often as a consequence of amplification. TRAF4 encodes an adaptor protein that belongs to the TRAF protein family. While most TRAF proteins influence immune and inflammation processes, TRAF4 is mainly involved in developmental and morphogenic processes. Interestingly, this protein has been shown to be linked to crucial cellular functions such as cell polarity and the regulation of reactive oxygen species production.
Keywords: TRAF; reactive oxygen species; cell polarity; morphogenesis; cancerogenesis; smurf TRAF; reactive oxygen species; cell polarity; morphogenesis; cancerogenesis; smurf

1. Introduction

The understanding of the molecular alterations involved in cancer development must take into account the heterogeneity of the tumors. This is a prerequisite for precise prognosis assessment and ultimately the development of adapted therapeutic strategies. A high level of expression of a subset of genes is a common alteration found in cancers. Indeed, overexpression is one of the mechanisms that leads to the activation of proto-oncogenes to oncogenes [1]. The Tumor Necrosis Factor (TNF) Receptor Associated Factor 4 (TRAF4) gene was identified due to its high expression in breast cancers [2,3]. TRAF4 was originally called Metastatic Lymph Node (MLN) 62 and CART1 (C-rich motif associated with RING and TRAF containing protein 1) [3,4]. This gene encodes a member of the TRAF family, a group of scaffold proteins that link TNFR and Toll/IL-1 family members to signaling cascades [5-7]. Recently, the function of TRAF4 was shown to be linked with specific cellular processes such as reactive oxygen species production and cell polarity. In this review, we discuss the recently identified roles of TRAF4 and its essential function during embryonic development.

2. TRAF4 belongs to the TRAF Protein Family

The TRAF protein family is composed of seven members that share a common structural organization (Figure 1) [2,6,8-10]. All TRAF proteins contain a C-terminal TRAF domain except TRAF7 where this domain is substituted by seven WD40 repeats [11,12]. The TRAF domain, which is involved in the homo- and heterotrimerization of TRAF proteins is mushroom-like in shape with a stalk-like N-TRAF and a cap-like C-TRAF [11,13-16]. The N-TRAF domain forms a trimeric parallel coiled-coil conformation [11]; in TRAF4, this region is short compared with other TRAF family members as it contains only 3 heptads while other TRAF proteins contain more than 10 heptads [4]. This difference might explain the poor ability of TRAF4 to associate with other TRAF proteins [17]. The C-TRAF domain forms an eight-stranded β-sandwich, a fold that is not restricted to TRAF proteins. Indeed, this domain is also known as the meprin and TRAF-C homology (MATH) domain because of its sequence homology with the meprin extracellular metalloprotease family [18-20]. The C-TRAF domain is involved in the trimerization of TRAF proteins. Moreover, it serves as the docking site of upstream partners during signaling by interacting directly with membrane receptors or indirectly with proteins attached to these receptors. For instance, key surface residues of the TRAF2 C-TRAF domain are involved in its interaction with the TNF receptor superfamily member, TNFR2 [14]. The N-TRAF domain is also involved in protein-protein interactions such as in TRAF2 where it is the binding site for the E3-ligase c-IAP2 [21].

All TRAFs, except TRAF1, contain two additional domains, an N-terminal RING (Really Interesting New Gene) finger motif and several successive zinc fingers. The RING domain is characterized by a C3HC4 motif which forms two zinc fingers [22]. However, TRAF4, 5, 6 and 7 contain a C3HC3D motif [4]. The RING domain mediates a crucial step in the ubiquitination pathway by simultaneously binding ubiquitination enzymes and their substrates, hence functioning as an E3-ligase [23]. However, the function of the TRAF4 RING domain as an E3-ligase has not yet been demonstrated. The central part of TRAF4 is formed by a cysteine-rich region that was previously defined as the association of three CART domains [4]. Each CART domain was proposed to be composed of two HC3HC3 zinc fingers. However, the solution NMR structure of the cysteine-rich central region (PDB ID: 2YUC, 2EOD) suggests that this part of TRAF4 is likely composed of 7 successive zinc fingers as previously proposed by several authors [6,24]. The first six zinc fingers have a C2HC structure while the seventh has a C2H2 structure (Figure 1). These data are consistent with the crystal structure of the zinc-finger region of TRAF2 and 6 [25,26].

Unlike other members of the TRAF protein family, TRAF4 does not associate with most members of the TNFR family. For instance, while TRAF1, 2, 3, 5, 6 have been reported to be directly or indirectly recruited to the cytoplasmic tail of CD40 (TNFR superfamily member 5), TRAF4 does not interact with this receptor [28-31]. However, weak interactions between TRAF4 and Lymphotoxin β receptor (LTβR) or Nerve Growth Factor Receptor (NGFR alias p75 neurotrophin receptor) have been reported, although the physiological relevance of these interactions remains poorly understood [32,33]. In agreement with these data, overexpression of TRAF4, unlike other members of the TRAF family, fails to activate NF-κB [34].

The primary structure of TRAF4 suggests that this protein, despite some differences, must share similar functional characteristics with other TRAF proteins. TRAF4 is likely to be involved in signal transduction as its TRAF domain mediates the direct or indirect interaction with a transmembrane receptor. Moreover, TRAF4 may possess E3-ligase activity through its RING domain which could mediate the poly-ubiquitination of target proteins and lead to their activation or degradation. However, the identity of the signaling pathway and the potential molecular targets of its putative E3-ligase activity remain unknown.

3. TRAF4 has a Special Place during Evolution

TRAF genes arose early during evolution. This protein family is represented by one member DG17 (alias zfaA) in the social amoeba Dictyostelium discoideum where it is expressed during the aggregation step of the life cycle of these unicellular organisms, when individual cells aggregate to form a multicellular colony [4,35]. TRAF family members are also present in Metazoans. One TRAF protein HyTRAF1 has been identified in the hydroid Hydractinia echinata [36]. HyTRAF1 is proposed to be involved in the regulation of apoptosis owing to its high expression during larval stages [36]. In Caenorhabditis elegans, this family is still represented by a single member named ceTRAF [37]. In Drosophila, the TRAF protein family is more diversified with three members, DTRAF1 to DTRAF3. Finally, in mammals 7 members are present and among them TRAF7 has a peculiar place as it is devoid of a TRAF domain. Sequence analysis of the TRAF family members in these different species suggests that human TRAF4 and TRAF6 are the oldest members, while TRAF1, 2, 3 and 5 arose later during vertebrate evolution [18,38]. Interestingly, the emergence of the TNFR family also occurred during this later period, suggesting that the last four TRAF proteins have a dedicated function that is directly linked to TNFR proteins. Given the observed major role of TRAF proteins during embryonic development of invertebrates and the major roles of TRAF4 orthologs in similar processes in vertebrates, TRAF4 may well be the TRAF family member with an ancestral morphogenetic function independent of TNFR [39].

4. TRAF4 Is Overexpressed in Cancers

TRAF4 was initially identified in breast cancer from a differential screen between metastatic lymph nodes and benign fibrodenomas biopsies [3]. TRAF4 is located in the q11.2 region of the long arm of chromosome 17, close to the ErbB2 oncogene [3,4]. TRAF4 mRNA was shown to be overexpressed in approximately one-quarter of breast cancers as a consequence of gene amplification [40]. This was subsequently confirmed by comparative genomic hybridization (CGH) and cDNA microarrays [41-43]. Interestingly TRAF4 overexpression is not limited to breast cancers. Indeed, it has been found in 43% of 623 human tumor samples from lung, ovary, prostate and colon among others [44]. In this latter study, TRAF4 overexpression is caused by gene amplification in about one-third of the tumors. TRAF4 protein overexpression is therefore a common feature of human cancers. Accordingly, TRAF4 was identified in a meta-analysis of 40 independent microarray studies as one of the 67 genes whose overexpression is characteristic of carcinomas [45]. TRAF4 overexpression is always observed in cancer cells and never in stromal cells. Its subcellular localization is variable and is cytoplasmic and/or membrane-associated (Figure 2), but nuclear localization is also observed in about 20% of TRAF4-positive tumors [4,44]. Interestingly, the membrane-association of TRAF4 seems to be correlated with tumor cell polarity and differentiation (Figure 2). These studies strongly suggest that TRAF4 plays an important role in carcinogenesis. Interestingly, in breast cancers, TRAF4 amplification can occur independently of ErbB2 amplification suggesting that TRAF4 may be the target of a more centromeric amplicon than the one involving ErbB2 [40,44]. Collectively, these data suggest that TRAF4 is not only a marker of human carcinomas, but also a candidate oncogene.

In line with its elevated expression in tumors and its inclusion in the TRAF protein family, TRAF4 has been hypothesized to be involved in apoptosis. For instance, TRAF4 provides resistance to an apoptotic stimulus in HEK293 cells [46]. When treated with an agonistic anti-Fas antibody, HEK293 cells normally undergo apoptosis; however, TRAF4 overexpression in these cells strongly decreases induced-cell death, arguing for an anti-apoptotic function for TRAF4 [46]. Paradoxically, other studies have shown that TRAF4 might also exert pro-apoptotic functions. Indeed, TRAF4 is regulated by members of the p53 protein family, namely p53 and p63 [47,48]. Hence, TRAF4 can be up-regulated by a temperature sensitive p53 or by its overexpression, as well as by the stabilization of p53 in response to DNA damage. Moreover, induction of apoptosis by irradiation in human lymphocytes or in noise-exposed cochlea cells increases their expression of TRAF4 [49,50]. Interestingly, TRAF4 overexpression induces apoptosis and suppresses colony formation in cell lines of different origins, regardless of their p53 status. The apparent discrepancy among these results may reveal a cell-type specific role for TRAF4 in life and death decisions.

The elevated expression of TRAF4 in many carcinomas suggests that this protein might have an important role in cancer which could be linked to cell polarity or apoptosis regulation.

5. TRAF4 has Restricted Functions in Immunity

TRAF proteins interact with Toll/IL1R and TNFR receptor family members to induce immune and inflammatory responses through NF-κB and MAPK activation [6]. However, TRAF4 involvement in these mechanisms remains poorly understood. Indeed, TRAF4 activates or inhibits NF-κB pathway depending on the ligand/receptor pair; for instance, TRAF4 potentiates NF-κB activation triggered by glucocorticoid-induced TNFR (GITR) but inhibits LPS-induced NF-κB activation [51,52].

The role of TRAF4 in immunity was studied in TRAF4-deficient mice. TRAF4-deficient mice do not show defects in T and B lymphocytes, granulocytes, macrophages and dendritic cell differentiation [53]. Moreover, the function of neutrophils and T cells is unaffected. The only observed phenotype is reduced dendritic cell migration [53]. However, TRAF4-deficient mice have not been challenged for bacterial resistance or autoimmune diseases and a role for TRAF4 in these processes cannot be ruled out.

Recently, TRAF4 has been proposed as a key negative regulator of NOD2 (nucleotide-binding oligomerization domain containing 2) signaling [54]. NOD2 is an intracellular pattern recognition receptor which plays an important role in immunologic homeostasis [55]. The NOD2 gene is linked to inflammatory diseases such as Crohn's Disease and Blau syndrome. TRAF4 inhibits NOD2-induced NF-κB activation through direct binding to NOD2 and NOD2-induced bacterial killing [54].

Thus, TRAFs are key proteins in innate and adaptative immune signaling with positive and negative regulatory functions. TRAF4 seems to be a negative regulator of immunity in specific processes of innate immunity.

6. TRAF4 Regulates Reactive Oxygen Species (ROS) Production

ROS act as signaling molecules that mediate growth-related responses such as angiogenesis. As a result, abnormal ROS production is implicated in various diseases including atherosclerosis, cardiovascular problems and cancers [56,57]. The NADPH oxidase Nox2 is a multi-subunit complex comprising two membrane-bound subunits, gp91phox (Nox2) and p22phox, three cytoplasmic subunits, p47phox, p40phox and p67phox, and the small GTP-binding protein, Rac1/2 [58]. This complex generates superoxide by transferring electrons to molecular oxygen [57]. Superoxide is involved in bacterial killing, inflammation and endothelial activation. To better understand the molecular mechanisms of superoxide synthesis regulation, a two-hybrid screen using p47phox as a bait allowed the recovery of TRAF4 [59]. The C-terminal part of p47phox interacts with the TRAF domain of TRAF4. Coexpression of p47phox and TRAF4 induces JNK activation and ROS production whereas each alone does not appreciably affect these functions [59]. Acute response to TNF-α induces a rapid PKC-dependent p47phox phosphorylation [60]. This post-translational modification enhances p47phox-TRAF4 association and translocation to the cell membrane leading to NADPH oxidase activation and ROS generation. Moreover, ROS-induced ERK1/2 and p38MAPK activation requires both p47phox and TRAF4 [60]. In addition, TRAF4 and p47phox target nascent lamellar focal complexes of motile endothelial cells in association with the paxillin paralogue Hic-5 to initiate Rho GTPase signaling [61]. Downregulation of one of these proteins is sufficient to inhibit endothelial cell migration.

In a recent report, TRAF4 and p47phox were identified as binding partners for GPIb-IX-V and GPVI, two platelet glycoprotein receptors that respectively bind to Von Willebrand Factor (VWF) and collagen and initiate thrombosis [62]. These two receptors initiate signaling events leading to the activation of platelet integrin which mediates platelet aggregation. The cytoplasmic regions of GPIb-IX-V and GPVI interact with the TRAF domain of TRAF4 and with the SH3 domain of p47phox in a complex with Hic-5 [62]. Since the regulation of platelet adhesion receptors by redox changes remains poorly understood, this novel interaction could link these receptors to redox signaling pathways.

Together these studies indicate that TRAF4 forms part of a complex that regulates ROS production by the NADPH oxidase Nox2 and couples this regulation to cell migration.

7. TRAF4 and Cell Polarity

TRAF4 has been detected in several cellular compartments: the plasma membrane, the cytoplasm and the nucleus [2,4,44]. When expressed in cells, TRAF4 is mainly found in the insoluble fractions of cell extracts [63]. Moreover, TRAF4 was shown to be associated with cytoskeleton- and membrane-containing fractions [59]. This membrane association is also observed in cells overexpressing TRAF4 where it accumulates at cell-cell contacts [64,65]. In in vitro polarized epithelial cells, TRAF4 localizes apically in cell-cell junctions, where it co-localizes with markers of tight junctions (TJ) such as occludin or Zonula Occludens-1 (ZO1) [65]. In normal human mammary samples, TRAF4 is found in TJ typical honeycomb patterns in epithelial cells (Figure 3). The association with TJ is highly dynamic as demonstrated by fluorescence recovery after photobleaching (FRAP) experiments, which show that TRAF4 shuttles between TJs and the cytoplasm. These data suggest that TRAF4 might be a signal transducer of intercellular junctions in normal epithelial cells. In contrast, in poorly differentiated epithelial cancer cells, the protein is either diffuse in the cytoplasm, or in cytoplasmic or nuclear foci, suggesting that this function is impaired (Figure 2) [65].

TJs are major cell-cell contact structures essential for the establishment and the maintenance of apico-basal polarity. A key regulator of cell polarity is TGF-β which is involved in the epithelial-mesenchymal transition (EMT), a process that allows cells to lose their polarity and cell-cell contact and acquire a mesenchymal phenotype. An intriguing link between the TRAF4 and TGF-β pathways came from the identification of TRAF4 as a potential interacting partner of Smurf1 and Smurf2 in two-hybrid screens [66-68]. Smurf (SMAD specific E3 ubiquitin protein ligase) proteins (Smurf1 and Smurf2) are related E3 ubiquitin ligases of the C2-WW-HECT class that regulate the TGFβ signaling pathway, motility, epithelial polarity and planar cell polarity [69,70]. In vitro assays confirmed that Smurf1 interacts with TRAF4 through 3 PXXY motifs located in the RING, zinc fingers and TRAF domains [67]. When ectopically expressed in cells, TRAF4 and Smurf1 co-localize in structures associated with the cell membrane [68]. Smurf1 was further shown to induce TRAF4 ubiquitination which in turn promoted TRAF4 26S proteasome-dependent degradation [67,68]. Thus Smurf1 can regulate TRAF4 protein levels through its E3-ligase activity.

Interesting data have come from the study of asymmetric cell division in Drosophila. In this organism, neuroblasts divide perpendicularly to the surface in the procephalic neurogenic region, and segregate the cell fate determinants Prospero (Pros) and Numb and their adaptor protein Miranda (Mira) into the future ganglion mother cells (GMCs) [71,72]. Interestingly DTRAF1, the ortholog of TRAF4, is asymmetrically localized to the apical cortex in mitotic neuroblasts [72]. This localization relies on Bazooka, the Drosophila ortholog of the polarity protein Par3 (Partitioning defective 3 homolog) with which DTRAF1 interacts, and depends on Eiger, the ortholog of TNF [72]. Thus DTRAF1 binds to Bazooka and acts downstream of Eiger in the Mira/Pros pathway during asymmetric division [73].

These studies suggest that mammalian TRAF4, located in the TJ of polarized epithelial cells and whose function in these structures might be linked to the TGF-β pathway, may be important in asymmetric division in specific cell types.

8. TRAF4 is Essential in Developmental Processes

TRAF4 function has been studied in different animal models. We summarize below the different findings obtained in each organism.


TRAF4 has been demonstrated to be essential in mice. TRAF4-deficient mice on a mixed 129/SvJ X C57BL/6 genetic background showed important defects of the upper respiratory tract [74]. On a pure 129/SvJ background this phenotype is more drastic and leads to 30% embryonic lethality [75]. Moreover, TRAF4-deficient survivors exhibit numerous less penetrant alterations, including dramatic malformations of the trachea and axial skeleton (ribs, sternum, tail), and defects in neural tube closure giving rise to mild spina bifida phenotypes [75]. Interestingly, these neural tube and skeletal defects are similar to those found in MEKK4-deficient mice, a MAP3K protein kinase of the STE11 family involved in the JNK/p38 pathway [76,77]. Some of these phenotypes might be linked to neural crest defects. Indeed, a TRAF4 mutant allele called msp2 (modifier of Sox10 expression pattern 2) alters neural crest patterning [78]. As discussed, defects in dendritic cells migration has also been reported in TRAF4-deficient mice which otherwise exhibit normal immune responses [53]. These null-phenotypes coincide with the embryonic expression pattern of murine TRAF4 [79]. Indeed, TRAF4 expression is highly regulated during development. It is widely expressed in various developing organs, with the highest levels observed during ontogenesis of the central (CNS) and peripheral (PNS) nervous systems, and in the nervous tissues of sensory organs. Thus, TRAF4 is a key molecule in diverse ontogenic processes, particularly in the nervous system [79]. In line with its potential role in the nervous system, TRAF4 expression was reported to be reduced in the temporal cortex of schizophrenic patients [80]. In adult mice, constitutive basal expression of TRAF4 is observed in most tissues, suggesting a general biological function for this protein [79]. A similar broad expression pattern is observed in human adult tissues [32,81]. Indeed, the promoter region of the TRAF4 gene does not have a consensus TATA box and contains a relatively weak Kozak sequence, two characteristics of ubiquitously expressed genes. Nonetheless, in mice, the hippocampus, the olfactive bulb, and the Purkinje cells of the cerebellum show strong TRAF4 expression, indicating that TRAF4 might also exert additional tissue-specific function(s) [79,82].


In zebrafish, two TRAF4 orthologs have been found, TRAF4a and TRAF4b [82]. Many mammalian genes have two zebrafish orthologs due to genome duplication during the evolution of these ray-finned fish [83]. Both TRAF4a and TRAF4b start to be expressed very early during embryogenesis. However, TRAF4b is ubiquitously and weakly expressed at all stages, while TRAF4a shows a highly restricted expression pattern mainly in sensorial and neural cells, and in the somites of embryos. Together, TRAF4a and TRAF4b have similar expression pattern as their mammalian counterpart [82].


The TGF-β pathway is a major signaling pathway during early developmental events in the Xenopus embryo. The E3 ubiquitin ligase Smurf1 negatively regulates TGF-β signaling, therefore, targets or partners of Smurf1 were proposed to participate in TGF-β signaling during embryonic processes [68]. TRAF4 was found in a yeast two-hybrid screen for Smurf1-interacting proteins. In the Xenopus embryo, two TRAF4 paralogs have been cloned, TRAF4a and TRAF4b, both of which are expressed within the neural plate and neural crest and are essential for neural crest development and normal neural plate folding [68]. TRAF4 is a positive effector of BMP (Bone morphogenetic protein) and Nodal, two TGF-β superfamily ligands. Indeed, endogenous TRAF4 is needed for the response of animal caps to these pathways. In contrast, TRAF4 has negligible effects on the Wnt (Wingless) and FGF (fibroblast growth factor) signaling, two other crucial pathways for neural crest specification.


The TRAF4 ortholog in Drosophila is DTRAF1 [84,85]. Homozygous flies carrying a null allele of DTRAF1 fail to develop to the pupal stage [86,87]. DTRAF1 seems to be necessary as early as the gastrulation stage as DTRAF1-deficient embryos show delays in ventral furrow formation [86]. Mutant larvae contain smaller imaginal discs, especially eye discs, form few axonal bundles and fail to defasciculate in the brain hemisphere. Heterozygous embryos show a dramatically enhanced thorax closure defect due to dominant negative expression of JNK (c-Jun N-terminal kinase) showing the importance of gene dosage [87]. Flies with a hypomorphic DTRAF1 mutation due to homozygous P-element insertion show supernumerary dorsal bristles, normally a typical structure of the fly peripheral nervous system [88]. Altogether, these results indicate that DTRAF1 is essential for thorax closure, development of imaginal eye discs and the formation of photosensory neuronal array in the brain hemisphere.

The reaper (rpr) gene is a key regulator of apoptosis during Drosophila embryogenesis [89]. DTRAF1 induces cell death through apoptosis signal-regulating kinase (ASK1) and JNK activation [88]. Drosophila inhibitor-of-apoptosis protein 1 (DIAP1) appears to negatively regulate apoptosis by triggering DTRAF1 proteasome-mediated degradation. Reaper, through DIAP1 inhibition, induces the stabilization of DTRAF1 and consequently JNK-mediated apoptosis. Misshapen (msn), an SPS1 (sporulation-specific 1) subfamily Ste20-related kinase, was shown to be an upstream activator of the JNK pathway required for dorsal closure. Msn directly binds to the TRAF domain of DTRAF1 and thereby potentiates DTRAF1-induced JNK activation [85].

Eiger, the Drosophila ortholog of TNF, is known to activate JNK and trigger apoptosis. An essential component of the Eiger-JNK pathway is dTAB2, the Drosophila ortholog of TAB2/3 (TGF-beta activated kinase 1(TAK1) binding protein 2/3). dTAB2 links DTRAF1 to the JNK kinase kinase, dTAK1, to form a triple complex [90]. This complex is recruited to the membrane through the interaction with DTRAF1 and the Eiger receptor, Wengen. This complex has an adaptor function which enables the presumptive JNKKKK Misshapen to activate dTAK1, which in turn advances the Eiger signal to the JNKK hemipterous and its substrate JNK. These data show that Eiger uses the dTAB2-DTRAF1-dTAK1 module to induce the JNK signaling pathway in Drosophila [90].

In Drosophila, the Toll signaling pathway regulates biological mechanisms such as dorso-ventral polarity, larval hematopoiesis and innate/adaptive immunity. Upon ligand binding to the Toll receptor, Pelle, a serine/threonine protein kinase homologous to the mammalian kinase IRAK (interleukin-1 receptor-associated kinase), becomes activated and phosphorylates itself and several other substrates. This leads to the activation and nuclear translocation of the Drosophila counterpart of mammalian NF-κB, Dorsal. DTRAF1 interacts with the regulatory N-terminal domain of Pelle [91]. Interestingly, coexpression of DTRAF1 and Pelle induces significant NF-κB activation whereas each alone does not. These data suggest that DTRAF1 is a component of the Toll pathway in Drosophila.

Altogether, these results show that the Drosophila ortholog of TRAF4, DTRAF1, is a key element of the JNK signaling pathway downstream of the Drosophila TNF pathway which is involved in several developmental processes. Interestingly, TRAF4 interacts with MEKK4 in human cells to activate JNK [92]. This suggests that TRAF4 may be involved in the JNK pathway together with MEKK4 in humans.

The study of TRAF4 in different model organisms has shed light on the crucial role of this protein in several physiological processes, in particular during embryonic development [39].

9. Conclusions

TRAF4 is overexpressed in many different types of carcinomas. However, the precise implication of this protein in cancer remains poorly understood. A clearer picture of its physiological function has, however, appeared. The study of TRAF4 in different organisms has revealed that it is involved in different morphogenic processes. Its function seems to be primordial with links to cell polarity and different pathways such as ROS production and TGF-β signaling.

Figure 1. Modular organization of the human TRAF4 protein. (a) TRAF4 is a 470 amino acid protein, harboring conserved RING, Zinc Finger (ZF1-ZF7) and TRAF domains. (b) Cartoon diagram of the nuclear magnetic resonance (NMR) solution structure of TRAF4 zinc finger motif 5 (PDB ID : 2EOD). Residues interacting with the zinc atom (red) are represented by green sticks. (c) Alignment of the zinc finger containing region of TRAF proteins performed with the ClustalX software [27]. Identical residues in all sequences are shown by an asterisk. Amino acids interacting with zinc atoms are highlighted in green. Residues corresponding to the sequence shown in panel b are in bold type.
Figure 1. Modular organization of the human TRAF4 protein. (a) TRAF4 is a 470 amino acid protein, harboring conserved RING, Zinc Finger (ZF1-ZF7) and TRAF domains. (b) Cartoon diagram of the nuclear magnetic resonance (NMR) solution structure of TRAF4 zinc finger motif 5 (PDB ID : 2EOD). Residues interacting with the zinc atom (red) are represented by green sticks. (c) Alignment of the zinc finger containing region of TRAF proteins performed with the ClustalX software [27]. Identical residues in all sequences are shown by an asterisk. Amino acids interacting with zinc atoms are highlighted in green. Residues corresponding to the sequence shown in panel b are in bold type.
Cancers 03 02734f1 1024
Figure 2. TRAF4 expression in normal breast and cancerous tissues. Immunohistochemistry of TRAF4 expression (brown) in normal breast (a), in situ carcinoma (b) and invasive carcinoma (c). Note that TRAF4 localization is modified from a predominantly membrane-associated presence in normal breast (a, arrows) to a mainly cytoplasmic presence in invasive tumor cells (c); in situ carcinomas represent an intermediate state in which TRAF4 remains associated focally with the membrane (b, arrows).
Figure 2. TRAF4 expression in normal breast and cancerous tissues. Immunohistochemistry of TRAF4 expression (brown) in normal breast (a), in situ carcinoma (b) and invasive carcinoma (c). Note that TRAF4 localization is modified from a predominantly membrane-associated presence in normal breast (a, arrows) to a mainly cytoplasmic presence in invasive tumor cells (c); in situ carcinomas represent an intermediate state in which TRAF4 remains associated focally with the membrane (b, arrows).
Cancers 03 02734f2 1024
Figure 3. TRAF4 is localized at tight junctions (TJs) of normal human mammary epithelial cells. TRAF4 (green) and ZO1 (red) were co-labeled on paraffin embedded sections of a normal human breast duct. Images are confocal section projections showing the typical honeycomb-like shape of tight junctions. Nuclei were stained using Hoechst-33258 (blue).
Figure 3. TRAF4 is localized at tight junctions (TJs) of normal human mammary epithelial cells. TRAF4 (green) and ZO1 (red) were co-labeled on paraffin embedded sections of a normal human breast duct. Images are confocal section projections showing the typical honeycomb-like shape of tight junctions. Nuclei were stained using Hoechst-33258 (blue).
Cancers 03 02734f3 1024


We thank Susan Chan, Valérie Kedinger and Catherine Tomasetto for critical reading of the manuscript. This work was supported by funds from the Institut National de la Santé et de la Recherche Médicale, the Centre National de la Recherche Scientifique, the Hôpital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, the Ligue Nationale contre le Cancer (Equipe labellisée LIGUE 2010) and the Comités du Haut-Rhin et du Bas-Rhin and the Institut National du Cancer. A.R. is a recipient of an allocation de recherche from the French Ministry of Research.


  1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. [Google Scholar]
  2. Kedinger, V.; Rio, M.C. TRAF4, the unique family member. Adv. Exp Med. Biol. 2007, 597, 60–71. [Google Scholar]
  3. Tomasetto, C.; Regnier, C.; Moog-Lutz, C.; Mattei, M.G.; Chenard, M.P.; Lidereau, R.; Basset, P.; Rio, M.C. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 1995, 28, 367–376. [Google Scholar]
  4. Regnier, C.H.; Tomasetto, C.; Moog-Lutz, C.; Chenard, M.P.; Wendling, C.; Basset, P.; Rio, M.C. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J. Biol. Chem. 1995, 270, 25715–25721. [Google Scholar]
  5. Lee, N.K.; Lee, S.Y. Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J. Biochem. Mol. Biol. 2002, 35, 61–66. [Google Scholar]
  6. Chung, J.Y.; Park, Y.C.; Ye, H.; Wu, H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 2002, 115, 679–688. [Google Scholar]
  7. Wajant, H.; Grell, M.; Scheurich, P. TNF receptor associated factors in cytokine signaling. Cytokine Growth Factor Rev. 1999, 10, 15–26. [Google Scholar]
  8. Dempsey, P.W.; Doyle, S.E.; He, J.Q.; Cheng, G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003, 14, 193–209. [Google Scholar]
  9. Bradley, J.R.; Pober, J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001, 20, 6482–6491. [Google Scholar]
  10. Inoue, J.; Ishida, T.; Tsukamoto, N.; Kobayashi, N.; Naito, A.; Azuma, S.; Yamamoto, T. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res. 2000, 254, 14–24. [Google Scholar]
  11. Rothe, M.; Wong, S.C.; Henzel, W.J.; Goeddel, D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78, 681–692. [Google Scholar]
  12. Xu, L.G.; Li, L.Y.; Shu, H.B. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J. Biol. Chem. 2004, 279, 17278–17282. [Google Scholar]
  13. McWhirter, S.M.; Pullen, S.S.; Holton, J.M.; Crute, J.J.; Kehry, M.R.; Alber, T. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc. Natl. Acad. Sci. USA 1999, 96, 8408–8413. [Google Scholar]
  14. Park, Y.C.; Burkitt, V.; Villa, A.R.; Tong, L.; Wu, H. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999, 398, 533–538. [Google Scholar]
  15. Li, C.; Norris, P.S.; Ni, C.Z.; Havert, M.L.; Chiong, E.M.; Tran, B.R.; Cabezas, E.; Reed, J.C.; Satterthwait, A.C.; Ware, C.F.; Ely, K.R. Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J. Biol. Chem. 2003, 278, 50523–50529. [Google Scholar]
  16. Ye, H.; Park, Y.C.; Kreishman, M.; Kieff, E.; Wu, H. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 1999, 4, 321–330. [Google Scholar]
  17. McWhirter, S.M.; Pullen, S.S.; Werneburg, B.G.; Labadia, M.E.; Ingraham, R.H.; Crute, J.J.; Kehry, M.R.; Alber, T. Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins. Cold Spring Harb Symp. Quant. Biol. 1999, 64, 551–562. [Google Scholar]
  18. Zapata, J.M.; Martinez-Garcia, V.; Lefebvre, S. Phylogeny of the TRAF/MATH domain. Adv. Exp. Med. Biol. 2007, 597, 1–24. [Google Scholar]
  19. Uren, A.G.; Vaux, D.L. TRAF proteins and meprins share a conserved domain. Trends Biochem. Sci. 1996, 21, 244–245. [Google Scholar]
  20. Zapata, J.M.; Pawlowski, K.; Haas, E.; Ware, C.F.; Godzik, A.; Reed, J.C. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J. Biol. Chem. 2001, 276, 24242–24252. [Google Scholar]
  21. Mace, P.D.; Smits, C.; Vaux, D.L.; Silke, J.; Day, C.L. Asymmetric recruitment of cIAPs by TRAF2. J. Mol. Biol. 2010, 400, 8–15. [Google Scholar]
  22. Freemont, P.S.; Hanson, I.M.; Trowsdale, J. A novel cysteine-rich sequence motif. Cell 1991, 64, 483–484. [Google Scholar]
  23. Deshaies, R.J.; Joazeiro, C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78, 399–434. [Google Scholar]
  24. Cheng, G.; Cleary, A.M.; Ye, Z.S.; Hong, D.I.; Lederman, S.; Baltimore, D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995, 267, 1494–1498. [Google Scholar]
  25. Yin, Q.; Lamothe, B.; Darnay, B.G.; Wu, H. Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry 2009, 48, 10558–10567. [Google Scholar]
  26. Yin, Q.; Lin, S.C.; Lamothe, B.; Lu, M.; Lo, Y.C.; Hura, G.; Zheng, L.; Rich, R.L.; Campos, A.D.; Myszka, D.G.; Lenardo, M.J.; Darnay, B.G.; Wu, H. E2 interaction and dimerization in the crystal structure of TRAF6. Nat. Struct. Mol. Biol. 2009, 16, 658–666. [Google Scholar]
  27. Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673–4680. [Google Scholar]
  28. Bishop, G.A.; Moore, C.R.; Xie, P.; Stunz, L.L.; Kraus, Z.J. TRAF proteins in CD40 signaling. Adv. Exp. Med. Biol. 2007, 597, 131–151. [Google Scholar]
  29. Leo, E.; Welsh, K.; Matsuzawa, S.; Zapata, J.M.; Kitada, S.; Mitchell, R.S.; Ely, K.R.; Reed, J.C. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation. J. Biol. Chem. 1999, 274, 22414–22422. [Google Scholar]
  30. Basaki, Y.; Ikizawa, K.; Kajiwara, K.; Yanagihara, Y. CD40-mediated tumor necrosis factor receptor-associated factor 3 signaling upregulates IL-4-induced germline Cepsilon transcription in a human B cell line. Arch. Biochem. Biophys. 2002, 405, 199–204. [Google Scholar]
  31. Pullen, S.S.; Miller, H.G.; Everdeen, D.S.; Dang, T.T.; Crute, J.J.; Kehry, M.R. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998, 37, 11836–11845. [Google Scholar]
  32. Krajewska, M.; Krajewski, S.; Zapata, J.M.; Van Arsdale, T.; Gascoyne, R.D.; Berern, K.; McFadden, D.; Shabaik, A.; Hugh, J.; Reynolds, A.; Clevenger, C.V.; Reed, J.C. TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. Am. J. Pathol. 1998, 152, 1549–1561. [Google Scholar]
  33. Ye, X.; Mehlen, P.; Rabizadeh, S.; VanArsdale, T.; Zhang, H.; Shin, H.; Wang, J.J.; Leo, E.; Zapata, J.; Hauser, C.A.; Reed, J.C.; Bredesen, D.E. TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction. J. Biol. Chem. 1999, 274, 30202–30208. [Google Scholar]
  34. Kawamata, S.; Hori, T.; Imura, A.; Takaori-Kondo, A.; Uchiyama, T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 1998, 273, 5808–5814. [Google Scholar]
  35. Driscoll, D.M.; Williams, J.G. Two divergently transcribed genes of Dictyostelium discoideum are cyclic AMP-inducible and coregulated during development. Mol. Cell Biol. 1987, 7, 4482–4489. [Google Scholar]
  36. Mali, B.; Frank, U. Hydroid TNF-receptor-associated factor (TRAF) and its splice variant: a role in development. Mol. Immunol. 2004, 41, 377–384. [Google Scholar]
  37. Wajant, H.; Muhlenbeck, F.; Scheurich, P. Identification of a TRAF (TNF receptor-associated factor) gene in Caenorhabditis elegans. J. Mol. Evol. 1998, 47, 656–662. [Google Scholar]
  38. Grech, A.; Quinn, R.; Srinivasan, D.; Badoux, X.; Brink, R. Complete structural characterisation of the mammalian and Drosophila TRAF genes: implications for TRAF evolution and the role of RING finger splice variants. Mol. Immunol. 2000, 37, 721–734. [Google Scholar]
  39. Mathew, S.J.; Haubert, D.; Kronke, M.; Leptin, M. Looking beyond death: a morphogenetic role for the TNF signalling pathway. J. Cell Sci. 2009, 122, 1939–1946. [Google Scholar]
  40. Bieche, I.; Tomasetto, C.; Regnier, C.H.; Moog-Lutz, C.; Rio, M.C.; Lidereau, R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res. 1996, 56, 3886–3890. [Google Scholar]
  41. Kauraniemi, P.; Barlund, M.; Monni, O.; Kallioniemi, A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001, 61, 8235–8240. [Google Scholar]
  42. Pollack, J.R.; Sorlie, T.; Perou, C.M.; Rees, C.A.; Jeffrey, S.S.; Lonning, P.E.; Tibshirani, R.; Botstein, D.; Borresen-Dale, A.L.; Brown, P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. USA 2002, 99, 12963–12968. [Google Scholar]
  43. Moelans, C.B.; de Wegers, R.A.; Monsuurs, H.N.; Maess, A.H.; van Diest, P.J. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol. (Dordr) 2011. [Google Scholar]
  44. Camilleri-Broet, S.; Cremer, I.; Marmey, B.; Comperat, E.; Viguie, F.; Audouin, J.; Rio, M.C.; Fridman, W.H.; Sautes-Fridman, C.; Regnier, C.H. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 2007, 26, 142–147. [Google Scholar]
  45. Rhodes, D.R.; Yu, J.; Shanker, K.; Deshpande, N.; Varambally, R.; Ghosh, D.; Barrette, T.; Pandey, A.; Chinnaiyan, A.M. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 2004, 101, 9309–9314. [Google Scholar]
  46. Fleckenstein, D.S.; Dirks, W.G.; Drexler, H.G.; Quentmeier, H. Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding partner for the p70S6 serine/threonine kinase. Leuk. Res. 2003, 27, 687–694. [Google Scholar]
  47. Gu, X.; Coates, P.J.; MacCallum, S.F.; Boldrup, L.; Sjostrom, B.; Nylander, K. TRAF4 is potently induced by TAp63 isoforms and localised according to differentiation in SCCHN. Cancer Biol. Ther. 2007, 6, 1986–1990. [Google Scholar]
  48. Sax, J.K.; El-Deiry, W.S. Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J. Biol. Chem. 2003, 278, 36435–36444. [Google Scholar]
  49. Turtoi, A.; Schneeweiss, F.H. Effect of (211)At alpha-particle irradiation on expression of selected radiation responsive genes in human lymphocytes. Int. J. Radiat. Biol. 2009, 85, 403–412. [Google Scholar]
  50. Hu, B.H.; Cai, Q.; Manohar, S.; Jiang, H.; Ding, D.; Coling, D.E.; Zheng, G.; Salvi, R. Differential expression of apoptosis-related genes in the cochlea of noise-exposed rats. Neuroscience 2009, 161, 915–925. [Google Scholar]
  51. Esparza, E.M.; Arch, R.H. TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation. Cell Mol. Life Sci. 2004, 61, 3087–3092. [Google Scholar]
  52. Takeshita, F.; Ishii, K.J.; Kobiyama, K.; Kojima, Y.; Coban, C.; Sasaki, S.; Ishii, N.; Klinman, D.M.; Okuda, K.; Akira, S.; Suzuki, K. TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur. J. Immunol. 2005, 35, 2477–2485. [Google Scholar]
  53. Cherfils-Vicini, J.; Vingert, B.; Varin, A.; Tartour, E.; Fridman, W.H.; Sautes-Fridman, C.; Regnier, C.H.; Cremer, I. Characterization of immune functions in TRAF4-deficient mice. Immunology 2008, 124, 562–574. [Google Scholar]
  54. Marinis, J.M.; Homer, C.R.; McDonald, C.; Abbott, D.W. A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J. Biol. Chem. 2011, 286, 1938–1950. [Google Scholar]
  55. Magalhaes, J.G.; Sorbara, M.T.; Girardin, S.E.; Philpott, D.J. What is new with Nods? Curr. Opin. Immunol. 2011, 23, 29–34. [Google Scholar]
  56. Ushio-Fukai, M. Localizing NADPH oxidase-derived ROS. Sci. STKE 2006, 2006, re8. [Google Scholar]
  57. Briones, A.M.; Touyz, R.M. Oxidative stress and hypertension: Current concepts. Curr. Hypertens. Rep. 2010, 12, 135–142. [Google Scholar]
  58. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. [Google Scholar]
  59. Xu, Y.C.; Wu, R.F.; Gu, Y.; Yang, Y.S.; Yang, M.C.; Nwariaku, F.E.; Terada, L.S. Involvement of TRAF4 in oxidative activation of c-Jun N-terminal kinase. J. Biol. Chem. 2002, 277, 28051–28057. [Google Scholar]
  60. Li, J.M.; Fan, L.M.; Christie, M.R.; Shah, A.M. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: Role of p47phox phosphorylation and binding to TRAF4. Mol. Cell Biol. 2005, 25, 2320–2330. [Google Scholar]
  61. Wu, R.F.; Xu, Y.C.; Ma, Z.; Nwariaku, F.E.; Sarosi, G.A., Jr.; Terada, L.S. Subcellular targeting of oxidants during endothelial cell migration. J. Cell Biol. 2005, 171, 893–904. [Google Scholar]
  62. Arthur, J.F.; Shen, Y.; Gardiner, E.E.; Coleman, L.; Kenny, D.; Andrews, R.K.; Berndt, M.C. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J. Thromb. Haemost. 2011, 9, 163–172. [Google Scholar]
  63. Dadgostar, H.; Cheng, G. Membrane localization of TRAF 3 enables JNK activation. J. Biol. Chem. 2000, 275, 2539–2544. [Google Scholar]
  64. Glauner, H.; Siegmund, D.; Motejadded, H.; Scheurich, P.; Henkler, F.; Janssen, O.; Wajant, H. Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4). Eur. J. Biochem. 2002, 269, 4819–4829. [Google Scholar]
  65. Kedinger, V.; Alpy, F.; Baguet, A.; Polette, M.; Stoll, I.; Chenard, M.P.; Tomasetto, C.; Rio, M.C. Tumor necrosis factor receptor-associated factor 4 is a dynamic tight junction-related shuttle protein involved in epithelium homeostasis. PLoS ONE 2008, 3, e3518. [Google Scholar]
  66. Colland, F.; Jacq, X.; Trouplin, V.; Mougin, C.; Groizeleau, C.; Hamburger, A.; Meil, A.; Wojcik, J.; Legrain, P.; Gauthier, J.M. Functional proteomics mapping of a human signaling pathway. Genome Res. 2004, 14, 1324–1332. [Google Scholar]
  67. Li, S.; Lu, K.; Wang, J.; An, L.; Yang, G.; Chen, H.; Cui, Y.; Yin, X.; Xie, P.; Xing, G.; He, F.; Zhang, L. Ubiquitin ligase Smurf1 targets TRAF family proteins for ubiquitination and degradation. Mol. Cell Biochem. 2010, 338, 11–17. [Google Scholar]
  68. Kalkan, T.; Iwasaki, Y.; Park, C.Y.; Thomsen, G.H. Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-beta signaling that affects neural crest formation. Mol. Biol. Cell 2009, 20, 3436–3450. [Google Scholar]
  69. Narimatsu, M.; Bose, R.; Pye, M.; Zhang, L.; Miller, B.; Ching, P.; Sakuma, R.; Luga, V.; Roncari, L.; Attisano, L.; Wrana, J.L. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 2009, 137, 295–307. [Google Scholar]
  70. Inoue, Y.; Imamura, T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008, 99, 2107–2112. [Google Scholar]
  71. Kraut, R.; Chia, W.; Jan, L.Y.; Jan, Y.N.; Knoblich, J.A. Role of inscuteable in orienting asymmetric cell divisions in Drosophila. Nature 1996, 383, 50–55. [Google Scholar]
  72. Wang, H.; Cai, Y.; Chia, W.; Yang, X. Drosophila homologs of mammalian TNF/TNFR-related molecules regulate segregation of Miranda/Prospero in neuroblasts. EMBO J. 2006, 25, 5783–5793. [Google Scholar]
  73. Peng, C.Y.; Manning, L.; Albertson, R.; Doe, C.Q. The tumour-suppressor genes lgl and dlg regulate basal protein targeting in Drosophila neuroblasts. Nature 2000, 408, 596–600. [Google Scholar]
  74. Shiels, H.; Li, X.; Schumacker, P.T.; Maltepe, E.; Padrid, P.A.; Sperling, A.; Thompson, C.B.; Lindsten, T. TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs. Am. J. Pathol. 2000, 157, 679–688. [Google Scholar]
  75. Regnier, C.H.; Masson, R.; Kedinger, V.; Textoris, J.; Stoll, I.; Chenard, M.P.; Dierich, A.; Tomasetto, C.; Rio, M.C. Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice. Proc. Natl. Acad. Sci. USA 2002, 99, 5585–5590. [Google Scholar]
  76. Abell, A.N.; Rivera-Perez, J.A.; Cuevas, B.D.; Uhlik, M.T.; Sather, S.; Johnson, N.L.; Minton, S.K.; Lauder, J.M.; Winter-Vann, A.M.; Nakamura, K.; Magnuson, T.; Vaillancourt, R.R.; Heasley, L.E.; Johnson, G.L. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol. Cell Biol. 2005, 25, 8948–8959. [Google Scholar]
  77. Chi, H.; Sarkisian, M.R.; Rakic, P.; Flavell, R.A. Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development. Proc. Natl. Acad. Sci. USA 2005, 102, 3846–3851. [Google Scholar]
  78. Buac, K.; Watkins-Chow, D.E.; Loftus, S.K.; Larson, D.M.; Incao, A.; Gibney, G.; Pavan, W.J. A Sox10 expression screen identifies an amino acid essential for Erbb3 function. PLoS Genet. 2008, 4, e1000177. [Google Scholar]
  79. Masson, R.; Regnier, C.H.; Chenard, M.P.; Wendling, C.; Mattei, M.G.; Tomasetto, C.; Rio, M.C. Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development. Mech. Dev. 1998, 71, 187–191. [Google Scholar]
  80. Aston, C.; Jiang, L.; Sokolov, B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 2004, 77, 858–866. [Google Scholar]
  81. Hsiao, L.L.; Dangond, F.; Yoshida, T.; Hong, R.; Jensen, R.V.; Misra, J.; Dillon, W.; Lee, K.F.; Clark, K.E.; Haverty, P.; Weng, Z.; Mutter, G.L.; Frosch, M.P.; MacDonald, M.E.; Milford, E.L.; Crum, C.P.; Bueno, R.; Pratt, R.E.; Mahadevappa, M.; Warrington, J.A.; Stephanopoulos, G.; Stephanopoulos, G.; Gullans, S.R. A compendium of gene expression in normal human tissues. Physiol. Genomics 2001, 7, 97–104. [Google Scholar]
  82. Kedinger, V.; Alpy, F.; Tomasetto, C.; Thisse, C.; Thisse, B.; Rio, M.C. Spatial and temporal distribution of the traf4 genes during zebrafish development. Gene Expr. Patterns 2005, 5, 545–552. [Google Scholar]
  83. Taylor, J.S.; Braasch, I.; Frickey, T.; Meyer, A.; Van de Peer, Y. Genome duplication, a trait shared by 22000 species of ray-finned fish. Genome Res. 2003, 13, 382–390. [Google Scholar]
  84. Preiss, A.; Johannes, B.; Nagel, A.C.; Maier, D.; Peters, N.; Wajant, H. Dynamic expression of Drosophila TRAF1 during embryogenesis and larval development. Mech. Dev. 2001, 100, 109–113. [Google Scholar]
  85. Liu, H.; Su, Y.C.; Becker, E.; Treisman, J.; Skolnik, E.Y. A Drosophila TNF-receptor-associated factor (TRAF) binds the ste20 kinase Misshapen and activates Jun kinase. Curr. Biol. 1999, 9, 101–104. [Google Scholar]
  86. Mathew, S.J.; Kerridge, S.; Leptin, M. A small genomic region containing several loci required for gastrulation in Drosophila. PLoS One 2009, 4, e7437. [Google Scholar]
  87. Cha, G.H.; Cho, K.S.; Lee, J.H.; Kim, M.; Kim, E.; Park, J.; Lee, S.B.; Chung, J. Discrete functions of TRAF1 and TRAF2 in Drosophila melanogaster mediated by c-Jun N-terminal kinase and NF-kappaB-dependent signaling pathways. Mol. Cell Biol. 2003, 23, 7982–7991. [Google Scholar]
  88. Kuranaga, E.; Kanuka, H.; Igaki, T.; Sawamoto, K.; Ichijo, H.; Okano, H.; Miura, M. Reaper-mediated inhibition of DIAP1-induced DTRAF1 degradation results in activation of JNK in Drosophila. Nat. Cell Biol. 2002, 4, 705–710. [Google Scholar]
  89. Kornbluth, S.; White, K. Apoptosis in Drosophila: neither fish nor fowl (nor man, nor worm). J. Cell Sci. 2005, 118, 1779–1787. [Google Scholar]
  90. Geuking, P.; Narasimamurthy, R.; Basler, K. A genetic screen targeting the tumor necrosis factor/Eiger signaling pathway: identification of Drosophila TAB2 as a functionally conserved component. Genetics 2005, 171, 1683–1694. [Google Scholar]
  91. Zapata, J.M.; Matsuzawa, S.; Godzik, A.; Leo, E.; Wasserman, S.A.; Reed, J.C. The Drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with Pelle and regulates NFkappaB activity. J. Biol. Chem. 2000, 275, 12102–12107. [Google Scholar]
  92. Abell, A.N.; Johnson, G.L. MEKK4 is an effector of the embryonic TRAF4 for JNK activation. J. Biol. Chem. 2005, 280, 35793–35796. [Google Scholar]
Back to TopTop